Hugel   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Seoul Korea, Republic of (2001)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
2008
NCT01791881
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Hugel

Active Ingredients

Drugs in Phase 4 Trials (1)

onabotulinumtoxinA (Botox) (9 trials)

Drugs in Phase 3 Trials (2)

abobotulinumtoxinA (Dysport) (1 trial)

rimabotulinumtoxinB (Myobloc) (4 trials)

Drugs in Phase 2 Trials (1)

bmt101 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blepharospasm (Phase 4)

Cerebral Palsy (Phase 3)

Cicatrix, Hypertrophic (Phase 2)

Dystonia (Phase 1)

Dystonic Disorders (Phase 1)

Hypertrophy (Phase 2)

Muscle Spasticity (Phase 3)

Paralysis (Phase 3)

Stroke (Phase 3)

Torticollis (Phase 1)

Urinary Bladder, Overactive (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial APIs: 4